SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Seel, Black sunshine
Search This Board:
Last Post: 6/30/2016 4:23:00 PM - Followers: 150 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IDRA News: Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti... 07:35 AM
IDRA News: Amended Statement of Changes in Beneficial Ownership (4/a) 06/29/2016 04:47:54 PM
IDRA News: Current Report Filing (8-k) 06/17/2016 09:07:15 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 06/15/2016 06:30:00 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 06/15/2016 05:42:39 PM
News News Alert: Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti... 07/01/2016 07:35:00 AM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#2464   Closing in on the 50 MA. Hopefully a rivervalley 06/30/16 04:23:00 PM
#2463   So many other green stocks today and this rivervalley 06/29/16 03:21:44 PM
#2462   :-D Cbdpotential 06/28/16 03:35:34 PM
#2461   Yeah true. Glad I sold off Friday Black sunshine 06/27/16 09:12:53 PM
#2460   5 year ibb. Citrati 06/27/16 04:13:39 PM
#2459   Brexit has IBB at its danger level now Citrati 06/27/16 03:25:55 PM
#2458   Just guessing, but a lot of people are Citrati 06/23/16 07:16:03 PM
#2457   Disappointing close today, especially day after conference. Black sunshine 06/22/16 06:25:24 PM
#2456   Hound, IDRA isn't the only bio looking weak. Citrati 06/21/16 02:04:27 PM
#2455   50/200 death cross imminent on weekly. TheHound 06/21/16 01:56:17 PM
#2454   Got back in yesterday small with 800 @ binks 06/21/16 12:00:04 PM
#2453   What does IDRA look like now? Citrati 06/21/16 09:24:07 AM
#2452   * * $IDRA Video Chart 06-16-16 * * ClayTrader 06/16/16 06:09:29 PM
#2451   NR, that is a good assessment IMO. Citrati 06/16/16 01:30:19 PM
#2450   What's up with this today? Is it noretreat 06/16/16 12:26:14 PM
#2449   I agree Looking good here imo And thank you :-D May Cbdpotential 06/14/16 09:40:41 AM
#2448   Scaling in is a good plan. Citrati 06/13/16 02:31:44 PM
#2447   Adding Cbdpotential 06/13/16 10:18:40 AM
#2445   Have a good feeling about next month :-D $idra Cbdpotential 06/08/16 03:09:37 AM
#2444   Looks like IBB is pushing IDRA downso far Citrati 06/07/16 10:30:47 AM
#2443   IDRA continues its building after some insty sales Citrati 05/23/16 10:21:46 AM
#2442   I got in on this at about 1.31, longhorn4lif 05/20/16 11:52:11 PM
#2441   According to form 4's, Citrati 05/16/16 03:51:18 PM
#2440   Support/resistance last 5 days. Citrati 05/16/16 11:45:09 AM
#2439   Baker Bro made another $35/share on their 10% Citrati 05/16/16 11:01:10 AM
#2438   Thankyou for the post Seel. Always appreciate and Citrati 05/12/16 11:23:34 PM
#2437   Yeah, biggest issue seems to be biotech being Black sunshine 05/12/16 09:28:12 PM
#2436   Finished the conference call. Catalyst quiet for a Seel 05/12/16 09:09:25 PM
#2435   It has been scary lately! And no sp Seel 05/12/16 09:02:32 PM
#2434   Ouch, horrible day for IDRA. Got stopped Black sunshine 05/12/16 05:31:22 PM
#2433   These are the levels/lines I am watching short term. Citrati 05/11/16 05:19:35 PM
#2432   u may get ur double bottom after all TheHound 05/11/16 03:22:01 PM
#2431   Haven't listened yet C. Hopefully will on Thursday Seel 05/10/16 08:00:24 PM
#2430   Didn't think this low would be here. Yeah, Citrati 05/10/16 02:19:24 PM
#2429   yeah, like what is going on. Ibb seems Citrati 05/10/16 11:01:38 AM
#2428   i didn't like the trading at yesterdays close. TheHound 05/10/16 10:41:41 AM
#2427   My vote is for a double bottom right here. Citrati 05/10/16 10:29:25 AM
#2426   http://seekingalpha.com/article/3973366-idera-pharmaceuticals-idra-ceo-vincent-m Citrati 05/09/16 11:55:14 PM
#2425   They obviously lied. No company would just disclose Phantom Lord 05/09/16 09:56:38 AM
#2424   Sure hope that holds. Guess we'll find Black sunshine 05/08/16 11:45:12 PM
#2423   Here's the 3 year look at IBB and Citrati 05/07/16 09:20:53 PM
#2422   Yep it has seriously underperformed since December, even Black sunshine 05/07/16 09:11:31 PM
#2421   Interesting to see the relationship of IBB to IDRA. Citrati 05/07/16 08:59:41 PM
#2420   Yeah nothing alarming there. Sure doesn't explain Black sunshine 05/07/16 08:40:46 PM
#2419   Have to see if there are more than Citrati 05/07/16 06:44:49 PM
#2418   A few guys on Stocktwits said they contacted Black sunshine 05/07/16 04:00:45 PM
#2417   "from what I heard an institution just dumped TheHound 05/07/16 02:31:00 PM
#2416   Small cap bios are generally out of favor Black sunshine 05/06/16 09:21:52 PM
#2415   What caused the big drop of the stock LGviolet 05/06/16 06:37:11 PM
#2414   wise TheHound 05/06/16 05:40:50 PM
PostSubject